Regression of melanoma, but not keratoacanthoma, is associated with increased HLA-B22 and decreased HLA-B27 and HLA-DR1

• Published in: Melanoma research Vol. 9; no. 6; p. 539
• Main Authors: Lowes, M A, Dunckley, H, Watson, N, Crotty, K, Cooke, B, Barnetson, R S, Halliday, G M
• Format: Journal Article
• Language: English
• Published: England 01.12.1999
• Subjects: Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - immunology; HLA-B Antigens - genetics; HLA-B Antigens - immunology; HLA-B27 Antigen - genetics; HLA-B27 Antigen - immunology; HLA-DR1 Antigen - genetics; HLA-DR1 Antigen - immunology; Humans; Keratoacanthoma - genetics; Keratoacanthoma - immunology; Melanoma - genetics; Melanoma - immunology; Neoplasm Regression, Spontaneous; Skin Neoplasms - genetics; Skin Neoplasms - immunology
• ISSN: 0960-8931
• DOI: 10.1097/00008390-199912000-00002

Sixty three Caucasian patients with either melanoma, keratoacanthoma or squamous cell carcinoma were human leucocyte antigen (HLA) typed. The regressing tumour groups were compared with their non-regressing counterparts, and the patient groups were compared with a control Caucasian population. Melanoma patients showing histological regression were more likely to be HLA-B22 positive, and HLA-B27 and -DR1 negative, than those without features of regression. When compared with a control population, the group of melanoma patients were more likely to be HLA-B22 positive. Comparison of the group of keratoacanthomas, a self-regressing tumour, and the group of squamous cell carcinomas, a non-regressing tumour, did not show any significant differences in HLA typing.